An Open Label Phase III Study of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine to Assess the Immunogenicity and Safety and to Investigate the Need for and Timing of a Booster Vaccination

Trial Profile

An Open Label Phase III Study of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine to Assess the Immunogenicity and Safety and to Investigate the Need for and Timing of a Booster Vaccination

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Influenza A vaccine H5N1-Baxter (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics
  • Sponsors Nanotherapeutics
  • Most Recent Events

    • 08 Oct 2015 Sponsor has been changed from Baxter healthcare corporation to Nanotherapeutics Inc. as reported by ClinicalTrials.gov record.
    • 09 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Planned end date changed from 1 Nov 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top